GlassScriptPhysician profile
Lindsay Karlin Bridgewater
NPI 1659781367
$11,024.13
in general payments reported to CMS, 2019-2025
22 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $5,850 · 2021: $152 · 2022: $285 · 2023: $3,042 · 2024: $1,448 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461 · Education: $1,080 · Travel and Lodging: $1,068 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Gift: $14.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.65 |
| Education | $1,079.99 |
| Travel and Lodging | $1,068.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Gift | $14.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,552.16 | 2020-2024 | Davinci Xi, Da Vinci Sp, Da Vinci Surgical System |
| Astellas Pharma US INC | $255.82 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $229.22 | 2019-2024 | |
| Caldera Medical, INC | $221.34 | 2023 | Desara |
| Sumitomo Pharma America, INC. | $150.91 | 2023-2025 | Myfembree |
| Scynexis, INC. | $80.59 | 2022 | |
| Coherus Oncology, INC. | $78.92 | 2023-2024 | |
| Applied Medical Resources Corporation | $70.72 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $57.45 | 2024-2025 | Keytruda |
| Axonics, INC. | $40.74 | 2023 | Axonics, Bulkamid |
| Boston Scientific Corporation | $37.08 | 2022 | |
| Pfizer INC. | $30.77 | 2024 | |
| Mayne Pharma Commercial LLC | $25.06 | 2023 | |
| Tactile Systems Technology INC | $24.65 | 2024 | Flexitouch Plus, Entre Plus |
| Glaxosmithkline, LLC. | $24.58 | 2023 | Jemperli |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.57 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $22.56 | 2023 | Lynparza |
| Mimedx Group, INC. | $21.72 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.37 | 2022 | |
| Daiichi Sankyo INC. | $19.72 | 2025 | Enhertu |
| Dysis Medical, INC. | $18.76 | 2022 | |
| Eisai INC. | $17.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Bridgewater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.